Vertex Pharmaceuticals Incorporated logo
Vertex Pharmaceuticals Incorporated (VRTX)
Compare

Vertex Pharmaceuticals Incorporated (VRTX) EV/FCF Ratio: 29.85x

popular:market cap|pe ratio|revenue|price history|total return

Is Vertex Pharmaceuticals Incorporated’s EV/FCF ratio high or low?

Vertex Pharmaceuticals Incorporated's EV/FCF ratio of 29.85x is 13% above its 5-year average of 26.41x, around the middle of its 5-year range (14.34x–39.65x).

The EV/FCF ratio for Vertex Pharmaceuticals Incorporated (VRTX) is 29.85x as of Tuesday, June 9, 2026. It is below its 12-month average by 7.19% (32.16x).

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

VRTX EV/FCF Ratio Chart

VRTX EV/FCF Ratio
29.85x-2.29% 1Y
Zoom

VRTX Average EV/FCF Ratio Chart

VRTX Current vs Average EV/FCF Ratio Chart

VRTX EV/FCF Ratio Metrics

EV/FCF RATIO

29.85x

EV/FCF RATIO AVG TTM

32.16x

EV/FCF RATIO AVG 3Y

29.52x

EV/FCF RATIO AVG 5Y

26.41x

EV/FCF RATIO AVG 10Y

108.80x

EV/FCF RATIO AVG 15Y

448.18x

EV/FCF RATIO AVG 20Y

448.18x

CURRENT VS TTM AVG

-7.19%

CURRENT VS 3Y AVG

+1.10%

CURRENT VS 5Y AVG

+13.02%

CURRENT VS 10Y AVG

-72.57%

CURRENT VS 15Y AVG

-93.34%

CURRENT VS 20Y AVG

-93.34%

VRTX Competitors' EV/FCF Ratio

NAMEMARKET CAPEV/FCF RATIOTTM3Y5Y
Vertex Pharmaceuticals Incorporated (VRTX)—29.85x32.16x29.52x26.41x
Bristol-Myers Squibb Company (BMY)$115.34B12.62x10.43x11.39x12.31x
Medtronic plc (MDT)$105.25B24.50x27.46x27.63x28.48x
CVS Health Corporation (CVS)$123.84B26.09x27.81x26.92x21.11x
Danaher Corporation (DHR)$133.37B27.74x31.99x32.29x30.49x
Elevance Health Inc. (ELV)$92.17B17.94x23.56x49.66x36.13x
Pfizer Inc. (PFE)$146.48B22.15x19.73x27.31x21.37x
Cigna Corporation (CI)$78.04B13.29x17.20x14.87x15.23x
Intuitive Surgical, Inc. (ISRG)$151.09B53.44x80.01x160.53x125.18x
Gilead Sciences, Inc. (GILD)$155.82B16.81x18.52x16.04x14.51x

Cash Flow Valuation Comparison

EV/FCF

29.9x

P/FCF

30.8x

FCF Yield

3.25%

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

  • EV/FCF accounts for debt and cash through enterprise value
  • P/FCF only considers equity value
  • EV/FCF can be compared across companies with different debt levels
  • Both measure how the market values cash generation

Vertex Pharmaceuticals Incorporated EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Vertex Pharmaceuticals Incorporated EV/FCF Ratio FAQ

What is the EV/FCF ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
The EV/FCF ratio for VRTX stock is 29.85x.
Is Vertex Pharmaceuticals Incorporated's EV/FCF ratio high or low?
Vertex Pharmaceuticals Incorporated's EV/FCF ratio of 29.85x is 13% above its 5-year average of 26.41x, around the middle of its 5-year range (14.34x–39.65x).
What is the TTM average EV/FCF ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
The TTM average EV/FCF ratio for VRTX stock is 32.16x.
What is the 3Y average EV/FCF ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
The 3Y average EV/FCF ratio for VRTX stock is 29.52x.
What is the 5Y average EV/FCF ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
The 5Y average EV/FCF ratio for VRTX stock is 26.41x.
What is the 10Y average EV/FCF ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
The 10Y average EV/FCF ratio for VRTX stock is 108.80x.
What is the 15Y average EV/FCF ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
The 15Y average EV/FCF ratio for VRTX stock is 448.18x.
What is the 20Y average EV/FCF ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
The 20Y average EV/FCF ratio for VRTX stock is 448.18x.

Vertex Pharmaceuticals Incorporated EV/FCF Ratio History

DATEEV/FCF RATIO
2026-06-0929.85x
2026-06-0829.65x
2026-06-0529.92x
2026-06-0429.57x
2026-06-0328.64x
2026-06-0228.42x
2026-06-0129.34x
2026-05-2929.97x
2026-05-2830.00x
2026-05-2729.26x
2026-05-2629.17x
2026-05-2229.07x
2026-05-2129.00x
2026-05-2028.79x
2026-05-1929.06x
2026-05-1829.21x
2026-05-1529.24x
2026-05-1430.17x
2026-05-1330.35x
2026-05-1230.02x
2026-05-1129.12x
2026-05-0828.75x
2026-05-0728.41x
2026-05-0628.60x
2026-05-0528.37x
2026-05-0434.09x
2026-05-0133.62x
2026-04-3033.89x
2026-04-2933.56x
2026-04-2834.11x
2026-04-2733.78x
2026-04-2434.13x
2026-04-2334.51x
2026-04-2234.72x
2026-04-2134.63x
2026-04-2034.84x
2026-04-1735.00x
2026-04-1634.56x
2026-04-1535.04x
2026-04-1435.25x
2026-04-1334.91x
2026-04-1034.61x
2026-04-0935.45x
2026-04-0835.22x
2026-04-0734.25x
2026-04-0634.45x
2026-04-0234.80x
2026-04-0135.49x
2026-03-3135.43x
2026-03-3035.16x
2026-03-2734.35x
2026-03-2636.01x
2026-03-2536.11x
2026-03-2435.60x
2026-03-2335.81x
2026-03-2036.03x
2026-03-1936.35x
2026-03-1835.83x
2026-03-1736.71x
2026-03-1637.00x
2026-03-1337.26x
2026-03-1237.96x
2026-03-1139.10x
2026-03-1039.65x
2026-03-0936.58x
2026-03-0636.24x
2026-03-0536.57x
2026-03-0437.94x
2026-03-0337.65x
2026-03-0238.60x
2026-02-2739.46x
2026-02-2638.12x
2026-02-2538.36x
2026-02-2438.71x
2026-02-2338.19x
2026-02-2037.86x
2026-02-1937.25x
2026-02-1837.34x
2026-02-1737.90x
2026-02-1339.03x
2026-02-1234.96x
2026-02-1134.67x
2026-02-1034.85x
2026-02-0935.42x
2026-02-0635.96x
2026-02-0534.49x
2026-02-0435.39x
2026-02-0335.01x
2026-02-0235.50x
2026-01-3035.34x
2026-01-2935.79x
2026-01-2835.96x
2026-01-2735.67x
2026-01-2635.88x
2026-01-2335.23x
2026-01-2235.14x
2026-01-2134.67x
2026-01-2033.19x
2026-01-1633.14x
2026-01-1532.95x
2026-01-1433.77x
2026-01-1334.17x
2026-01-1234.62x
2026-01-0934.88x
2026-01-0835.32x
2026-01-0736.44x
2026-01-0635.22x
2026-01-0533.71x
2026-01-0233.97x
2025-12-3134.06x
2025-12-3034.09x
2025-12-2934.56x
2025-12-2634.80x
2025-12-2434.81x
2025-12-2334.52x
2025-12-2234.60x
2025-12-1934.28x
2025-12-1833.60x
2025-12-1733.77x
2025-12-1634.19x
2025-12-1534.25x
2025-12-1233.96x
2025-12-1133.49x
2025-12-1033.39x
2025-12-0932.80x
2025-12-0833.19x
2025-12-0534.23x
2025-12-0434.37x
2025-12-0334.82x
2025-12-0232.50x
2025-12-0131.92x
2025-11-2832.54x
2025-11-2632.43x
2025-11-2532.25x
2025-11-2431.80x
2025-11-2132.01x
2025-11-2031.67x
2025-11-1931.57x
2025-11-1832.69x
2025-11-1732.57x
2025-11-1432.81x
2025-11-1332.61x
2025-11-1232.58x
2025-11-1132.20x
2025-11-1031.58x
2025-11-0730.68x
2025-11-0631.20x
2025-11-0531.26x
2025-11-0431.62x
2025-11-0330.53x
2025-10-3130.50x
2025-10-3030.08x
2025-10-2929.88x
2025-10-2830.26x
2025-10-2730.10x
2025-10-2430.19x
2025-10-2330.28x
2025-10-2230.56x
2025-10-2130.55x
2025-10-2030.02x
2025-10-1729.85x
2025-10-1629.24x
2025-10-1529.19x
2025-10-1429.51x
2025-10-1329.15x
2025-10-1029.18x
2025-10-0929.71x
2025-10-0830.17x
2025-10-0729.37x
2025-10-0628.82x
2025-10-0328.85x
2025-10-0229.26x
2025-10-0128.92x
2025-09-3027.99x
2025-09-2928.26x
2025-09-2627.55x
2025-09-2527.27x
2025-09-2426.88x
2025-09-2327.11x
2025-09-2227.36x
2025-09-1927.36x
2025-09-1827.65x
2025-09-1727.66x
2025-09-1627.97x
2025-09-1528.10x
2025-09-1228.20x
2025-09-1128.41x
2025-09-1027.76x
2025-09-0928.35x
2025-09-0828.26x
2025-09-0528.32x
2025-09-0428.38x
2025-09-0328.36x
2025-09-0228.68x
2025-08-2927.94x
2025-08-2828.02x
2025-08-2727.80x
2025-08-2627.66x
2025-08-2527.79x
2025-08-2228.25x
2025-08-2128.42x
2025-08-2028.19x
2025-08-1927.92x
2025-08-1827.86x
2025-08-1528.07x
2025-08-1427.89x
2025-08-1328.30x
2025-08-1227.70x
2025-08-1126.72x
2025-08-0826.13x
2025-08-0726.80x
2025-08-0627.55x
2025-08-0526.76x
2025-08-0432.47x
2025-08-0131.73x
2025-07-3131.34x
2025-07-3032.25x
2025-07-2932.19x
2025-07-2831.63x
2025-07-2532.28x
2025-07-2432.47x
2025-07-2332.82x
2025-07-2232.32x
2025-07-2131.46x
2025-07-1831.56x
2025-07-1731.81x
2025-07-1632.27x
2025-07-1531.88x
2025-07-1432.48x
2025-07-1132.22x
2025-07-1033.01x
2025-07-0932.97x
2025-07-0832.04x
2025-07-0731.53x
2025-07-0331.54x
2025-07-0231.35x
2025-07-0130.99x
2025-06-3030.48x
2025-06-2730.19x
2025-06-2630.34x
2025-06-2530.52x
2025-06-2430.85x
2025-06-2330.35x
2025-06-2030.16x
2025-06-1830.71x
2025-06-1730.24x
2025-06-1630.90x
2025-06-1331.23x
2025-06-1231.57x
2025-06-1131.01x
2025-06-1030.94x
2025-06-0930.55x
2025-06-0630.87x
2025-06-0530.37x
2025-06-0430.52x
2025-06-0330.57x
2025-06-0230.49x
2025-05-3030.24x
2025-05-2930.62x
2025-05-2830.47x

Showing the most recent 260 of 3,595 data points. The chart above shows the full history.

Related Metrics

Free Cash FlowFCF YieldP/FCF RatioEV/EBITDAAll Metrics

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.

Boston, MA
6,100 employees
www.vrtx.com
Healthcare / Biotechnology
Sector
Healthcare
Industry
Biotechnology
CEO
Reshma Kewalramani
View full financials